A detailed history of Nuveen Asset Management, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 349,905 shares of NKTR stock, worth $454,876. This represents 0.0% of its overall portfolio holdings.

Number of Shares
349,905
Holding current value
$454,876
% of portfolio
0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.9 - $1.83 $314,914 - $640,326
349,905 New
349,905 $433,000
Q1 2023

May 15, 2023

SELL
$0.64 - $3.15 $34,297 - $168,808
-53,590 Reduced 9.54%
508,137 $355,000
Q4 2022

Feb 14, 2023

SELL
$2.03 - $4.28 $173,979 - $366,813
-85,704 Reduced 13.24%
561,727 $1.27 Million
Q3 2022

Nov 14, 2022

SELL
$3.04 - $5.14 $38,750 - $65,519
-12,747 Reduced 1.93%
647,431 $2.07 Million
Q2 2022

Aug 15, 2022

BUY
$3.17 - $6.17 $635,328 - $1.24 Million
200,419 Added 43.59%
660,178 $2.51 Million
Q1 2022

May 16, 2022

SELL
$4.16 - $13.72 $22,272 - $73,456
-5,354 Reduced 1.15%
459,759 $2.62 Million
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $266,125 - $452,388
-24,573 Reduced 5.02%
465,113 $6.28 Million
Q3 2021

Nov 12, 2021

SELL
$13.07 - $18.84 $353,412 - $509,433
-27,040 Reduced 5.23%
489,686 $8.79 Million
Q2 2021

Aug 16, 2021

SELL
$16.52 - $20.4 $67,186 - $82,966
-4,067 Reduced 0.78%
516,726 $8.87 Million
Q1 2021

May 17, 2021

SELL
$16.56 - $25.46 $272,395 - $418,791
-16,449 Reduced 3.06%
520,793 $10.4 Million
Q4 2020

Feb 16, 2021

BUY
$15.77 - $19.03 $42,373 - $51,133
2,687 Added 0.5%
537,242 $9.13 Million
Q3 2020

Nov 16, 2020

SELL
$16.59 - $24.79 $118,220 - $176,653
-7,126 Reduced 1.32%
534,555 $8.87 Million
Q2 2020

Aug 14, 2020

SELL
$16.86 - $23.44 $628,608 - $873,936
-37,284 Reduced 6.44%
541,681 $12.5 Million
Q1 2020

May 14, 2020

BUY
$14.47 - $27.96 $3.47 Million - $6.71 Million
240,071 Added 70.84%
578,965 $10.3 Million
Q4 2019

Feb 14, 2020

SELL
$15.87 - $23.12 $3.15 Million - $4.59 Million
-198,454 Reduced 36.93%
338,894 $7.32 Million
Q3 2019

Nov 14, 2019

SELL
$16.91 - $36.27 $6.75 Million - $14.5 Million
-399,415 Reduced 42.64%
537,348 $9.79 Million
Q2 2019

Aug 15, 2019

BUY
$31.0 - $36.3 $29 Million - $34 Million
936,763 New
936,763 $33.3 Million
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $117,551 - $218,838
-3,863 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$46.46 - $68.49 $179,474 - $264,576
3,863 New
3,863 $235,000
Q2 2018

Aug 14, 2018

SELL
$46.25 - $104.45 $1.24 Million - $2.8 Million
-26,849 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$57.4 - $108.44 $1.1 Million - $2.08 Million
19,227 Added 252.26%
26,849 $2.85 Million
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $5.2 Million - $13.7 Million
-225,950 Reduced 96.74%
7,622 $0
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $4.16 Million - $5.61 Million
233,572
233,572 $5.61 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $244M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.